CR10607A - Derivado heterociclico fusionado y su uso - Google Patents

Derivado heterociclico fusionado y su uso

Info

Publication number
CR10607A
CR10607A CR10607A CR10607A CR10607A CR 10607 A CR10607 A CR 10607A CR 10607 A CR10607 A CR 10607A CR 10607 A CR10607 A CR 10607A CR 10607 A CR10607 A CR 10607A
Authority
CR
Costa Rica
Prior art keywords
compound
derivative
fusioned
heterociclic
cancer
Prior art date
Application number
CR10607A
Other languages
English (en)
Inventor
Nozomu Sakai
Shinichi Imamura
Naoki Miyamoto
Takaharu Hirayama
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR10607A publication Critical patent/CR10607A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion provee un derivado heterociclico fusionado que tiene una potente actividad inhibidora de quinasa y su uso. Un compuesto de la formula (I): en donde cada simbolo es como se define en la memoria descriptiva, excepto un compuesto particular, o una de sus sales, y un agente farmaceutico que contiene el compuesto o uno de sus profarmacos, que es un inhibidor de quinasa (VEGFR, VEGFR2, PDGFR, Raf), un inhibidor de angiogenesis, un agente para la prevencion o el tratamiento del cancer, un inhibidor del crecimiento del cancer o un supresor de la metastasis del cancer.
CR10607A 2006-08-04 2009-02-09 Derivado heterociclico fusionado y su uso CR10607A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006213981 2006-08-04
JP2006331230 2006-12-07
JP2007144072 2007-05-30

Publications (1)

Publication Number Publication Date
CR10607A true CR10607A (es) 2009-03-12

Family

ID=38996616

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10607A CR10607A (es) 2006-08-04 2009-02-09 Derivado heterociclico fusionado y su uso

Country Status (18)

Country Link
US (4) US8044049B2 (es)
EP (1) EP2049541B1 (es)
JP (1) JP5238697B2 (es)
KR (1) KR20090047509A (es)
AR (1) AR062207A1 (es)
AU (1) AU2007279595A1 (es)
BR (1) BRPI0714665A2 (es)
CA (1) CA2659971A1 (es)
CL (1) CL2007002261A1 (es)
CO (1) CO6150183A2 (es)
CR (1) CR10607A (es)
IL (1) IL196799A0 (es)
MA (1) MA30651B1 (es)
MX (1) MX2009001349A (es)
NO (1) NO20090986L (es)
PE (1) PE20080538A1 (es)
TW (1) TW200817409A (es)
WO (1) WO2008016192A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
US8058274B2 (en) * 2007-08-17 2011-11-15 Icagen, Inc. Heterocycles as potassium channel modulators
WO2009025358A1 (ja) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
EA201001365A1 (ru) 2008-02-28 2011-04-29 Новартис Аг ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДУЕМОГО C-МЕТ ТИРОЗИНКИНАЗОЙ
CN101372475B (zh) * 2008-03-19 2012-01-04 南京工业大学 芳杂环取代的二苯脲类衍生物及其用途
JPWO2009128520A1 (ja) 2008-04-18 2011-08-04 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する複素環化合物
WO2009136663A1 (en) * 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA020641B1 (ru) 2008-10-02 2014-12-30 Респайверт Лимитед Производные n-(1-фенил-3-алкилпиразол-5-ил)-n'-арилмочевины
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
LT3372605T (lt) 2008-10-22 2022-02-10 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
EP2370429B1 (en) 2008-12-11 2016-04-20 Respivert Limited P38 map kinase inhibitors
BRPI0923401B1 (pt) 2008-12-24 2021-11-23 Syngenta Limited Método para o preparo de aril amidas e composto
ES2427917T3 (es) 2009-02-10 2013-11-04 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5583845B2 (ja) 2010-04-28 2014-09-03 ブリストル−マイヤーズ スクイブ カンパニー イミダゾピリダジニル化合物および癌に対するそれらの使用
PT2694072T (pt) 2011-04-01 2018-02-26 Genentech Inc Combinação de composto inibidor de akt e abiraterona para utilização em tratamentos terapêuticos
EP2788345B1 (en) 2011-12-09 2020-06-10 Chiesi Farmaceutici S.p.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
US9988386B2 (en) 2013-05-30 2018-06-05 Kata Pharmaceuticals, Inc. Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof
WO2015084384A1 (en) * 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
MX2016007734A (es) 2013-12-13 2016-10-14 Eurochem Agro Gmbh Mezcla fertilizante que contiene inhibidor de la nitrificacion.
WO2016086026A1 (en) * 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
JPWO2016093299A1 (ja) * 2014-12-10 2017-09-21 千寿製薬株式会社 水性液剤
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
EP3478676A1 (en) 2016-06-29 2019-05-08 Orion Corporation Benzodioxane derivatives and their pharmaceutical use
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
EP3541431B1 (en) * 2016-11-16 2024-04-17 The General Hospital Corporation Myeloperoxidase imaging agents
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
WO2021075477A1 (ja) * 2019-10-16 2021-04-22 国立大学法人京都大学 運動神経細胞変性阻害剤
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022192732A1 (en) * 2021-03-12 2022-09-15 Gt Molecular, Llc Multiplexed genotyping assays with a single probe using fluorescent amplitude tuning
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024088379A1 (zh) * 2022-10-27 2024-05-02 香港科技大学 肿瘤的治疗或预防方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001478A1 (en) 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
WO1989001333A1 (en) 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JPH0820584A (ja) 1994-07-04 1996-01-23 Takeda Chem Ind Ltd イミダゾール誘導体及びその用途
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US6797823B1 (en) 1999-01-22 2004-09-28 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
MXPA02008021A (es) 2000-02-15 2004-04-05 Sugen Inc Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas.
EP1777218B1 (en) 2000-10-20 2008-12-31 Eisai R&D Management Co., Ltd. Process for the preparation of 4-phenoxy quinoline derivatives
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CN100582108C (zh) 2003-12-31 2010-01-20 先灵-普劳有限公司 通过使用咪唑并[1,2-b]哒嗪衍生物控制动物中的寄生虫
CA2586259A1 (en) * 2004-11-08 2006-05-11 Banyu Pharmaceutical Co., Ltd. Novel fused imidazole derivative
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
WO2007013673A1 (en) * 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008016131A1 (fr) * 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique à cycles fusionnés

Also Published As

Publication number Publication date
CA2659971A1 (en) 2008-02-07
CO6150183A2 (es) 2010-04-20
AU2007279595A1 (en) 2008-02-07
JP5238697B2 (ja) 2013-07-17
NO20090986L (no) 2009-05-04
US20100168424A1 (en) 2010-07-01
AR062207A1 (es) 2008-10-22
AU2007279595A2 (en) 2009-03-19
MA30651B1 (fr) 2009-08-03
IL196799A0 (en) 2009-11-18
US8273741B2 (en) 2012-09-25
WO2008016192A3 (en) 2008-05-08
US20090306374A1 (en) 2009-12-10
US8034812B2 (en) 2011-10-11
US20100273788A1 (en) 2010-10-28
TW200817409A (en) 2008-04-16
PE20080538A1 (es) 2008-06-18
KR20090047509A (ko) 2009-05-12
MX2009001349A (es) 2009-04-17
BRPI0714665A2 (pt) 2012-03-13
EP2049541B1 (en) 2015-09-23
CL2007002261A1 (es) 2008-05-02
JP2009545583A (ja) 2009-12-24
US8044049B2 (en) 2011-10-25
US20090137595A1 (en) 2009-05-28
EP2049541A2 (en) 2009-04-22
WO2008016192A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
CR10607A (es) Derivado heterociclico fusionado y su uso
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CR11430A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CR11199A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CL2015003442A1 (es) Derivados heterociclicos
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CO6361937A2 (es) Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
UY35361A (es) COMPUESTOS PERFLUORADOS DE 5,6-DIHIDRO-4H-1,3-OXAZIN-2-AMINA COMO INHIBIDORES DE BETA-SECRETASA y MÉTODOS DE USO
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
UY32585A (es) Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
UY29446A1 (es) Derivados de ciclopentapiridina y tetrahidroquinolina
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
UY30835A1 (es) 8-alquinilxantinas y derivados
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CL2017000006A1 (es) Derivados de quinolizinona como inhibidores de pi3k
BR112016026787A8 (pt) Derivados de quinzaolina-4(3h)-ona antibacterianos
ECSP099046A (es) Derivados ciclopropil amina
CL2017000105A1 (es) Novedosas pirimidinas 2,5-sustituidas.
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)